A cluster headache (CH) is a rare type of headache. The attack lasts for 15 minutes to three hours, occurs daily or almost daily for weeks or months. The causes of cluster headache appears to be related to the body's sudden release of histamine (a chemical in the body that is released during an allergic reaction) or serotonin (a chemical produced by nerve cells) in the area of a nerve situated in the face called the trigeminal nerve. A problem may be involved in a small area at the base of the brain called the hypothalamus. Cluster headache can be triggered by alcohol and smoking cigarette, high altitudes, bright lights, exertion, heat, foods rich in nitrite, certain drugs, and cocaine.
Some types of acute treatment (oxygen, tripants, octreotide, and others), preventive treatment (calcium channel blockers, corticosteroids, lithium carbonate, and others), and surgery in severe cases can provide some pain relief.
The global cluster headache market is estimated to be valued at US$ 355.2 Million in 2021 and is expected to increase to US$ 550.1 Million by 2028, witnessing a CAGR of 6.4% over the forecast period (2021-2028).
Figure 1. Global Cluster Headache Market Value (US$ Mn) & Y-o-Y Growth (%)
Increasing prevalence of cluster headache patients with a positive family history is expected to drive the growth of the global cluster headache market.
Increasing prevalence of cluster headache patients with a positive family history is expected to drive the growth of the global cluster headache market. For instance, according to a research article published by BMC (Bio med central) in April 2020, a systematic review and meta-analysis was carried out in accordance with the guidelines for preferred reporting items for systematic reviews and meta-analysis protocols (PRISMA- P). It was found that an estimated prevalence of CH patients with a family history was around 6.27% with an overall I2 of 73%.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2020 | Market Size in 2021: | US$ 355.2 Mn |
| Historical Data for: | 2017 to 2020 | Forecast Period: | 2021 to 2028 |
| Forecast Period 2021 to 2028 CAGR: | 6.4% | 2028 Value Projection: | US$ 550.1 Mn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Zosano Pharma, Eli Lilly and Company, Lundbeck Seattle BioPharmaceutical, Winston Laboratories, GlaxoSmithKline plc., ElectroCore Medical LLC, Autonomic Technologies, Inc., AstraZeneca plc., Allergan plc., Bayer AG, F. Hoffmann-La Roche Ltd, Novartis AG, Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Sanofi, and AbbVie Inc. |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Figure 2. Global Cluster Headache Market Share (%), By Region, 2021
Global Cluster Headache Market – Impact of Coronavirus (COVID-19) Pandemic
Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe. The coronavirus (COVID-19) pandemic and lockdown in various countries across the globe has impacted the financial status of businesses in all sectors. Private healthcare sector is one of the sector, which is majorly impacted by the COVID-19 pandemic.
The coronavirus pandemic has negatively impacted the development, production, and supply of pharmaceutical products and affected growth of the medication used in treatment of CH disease manufactured by various companies across the regions such as North America, Europe, and Asia Pacific. Moreover, the production and supply of pharmaceutical products is also affected due to lockdown imposed globally during the COVID-19 pandemic. Moreover, screen time of people during COVID-19 has continued to increase due to public health measures imposed by the government to contain the pandemic, which will drive the global market for cluster headache.
Global Cluster Headache Market: Restraint
Insufficient awareness among healthcare providers and unfavorable healthcare policies negatively impacting overall healthcare spending is hampering the global cluster headache market.
Key Players
Major players operating in the global cluster headache market include Zosano Pharma, Eli Lilly and Company, Lundbeck Seattle BioPharmaceutical, Winston Laboratories, GlaxoSmithKline plc., ElectroCore Medical LLC, Autonomic Technologies, Inc., AstraZeneca plc., Allergan plc., Bayer AG, F. Hoffmann-La Roche Ltd, Novartis AG, Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Sanofi, and AbbVie Inc.
Cluster headache is one of the most severe type of headache, as it occurs in cyclical patterns or cluster periods. Cluster episodes, which last from weeks to months, are frequently followed by remission periods, during which the headache stops. For months, if not years, there are no headaches during remission. Cluster headache is most frequently experienced between the ages of puberty and middle age, but it can strike anyone at any time. Cluster headache is divided into two categories: episodic and chronic. Episodic cluster headache occurs on a regular basis for one week to a year, followed by a month or more of headache-free time. Chronic cluster headache regularly occurs for more than a year, followed by a headache-free period lasting less than a month.
A person with episodic cluster headache may develop chronic cluster headache and vice versa. One-sided soreness, restlessness, excessive tears, redness of the eye on the afflicted side, runny nose on the affected side, and others are some of the symptoms. The dilatation, or widening, of the blood arteries that feed blood to the brain and face causes cluster headache. The trigeminal nerve, which sends sensations from the face to the brain, is compressed by this dilatation.
Market Dynamics
Increasing prevalence of cluster headache is anticipated to drive the growth of global cluster headache market over the forecast period. For instance, according to the article published in the National Center for Biotechnology Information in April 2018, cluster headache is a primary headache that affects up to 0.1% of the population globally. Patients suffer cluster headache attacks up to eight times a day lasting 15 to 180 minutes. The male to female ratio is approximately 2.5: 1.
Key features of the study:
Detailed Segmentation:
“*” marked represents similar segmentation in other categories in the respective section.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients